Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

South America Halitosis Treatment Market

ID: MRFR/MED/54794-HCR
200 Pages
Satyendra Maurya
Last Updated: February 06, 2026

South America Halitosis Treatment Market Research Report: Size, Share, Trend Analysis By Indication (Respiratory, Liver, Kidney, Gastrointestinal, Systemic, Others), By Diagnostic Tests (Halimeter, Gas Chromatography, BANA Test, -Galactosidase Activity Assay, Others), By Drug Treatment (Antacids, Antiseptics, Ranitidine, Others) and By Regional (Brazil, Mexico, Argentina, Rest of South America) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

South America Halitosis Treatment Market Infographic
Purchase Options
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Healthcare, BY Treatment Type (USD Million)
  49.     4.1.1 Mouthwash
  50.     4.1.2 Chewing Gum
  51.     4.1.3 Toothpaste
  52.     4.1.4 Sprays
  53.     4.1.5 Lozenges
  54.   4.2 Healthcare, BY Distribution Channel (USD Million)
  55.     4.2.1 Pharmacies
  56.     4.2.2 Online Retail
  57.     4.2.3 Supermarkets
  58.     4.2.4 Health Stores
  59.     4.2.5 Direct Sales
  60.   4.3 Healthcare, BY End User (USD Million)
  61.     4.3.1 Adults
  62.     4.3.2 Children
  63.     4.3.3 Elderly
  64.     4.3.4 Dental Patients
  65.     4.3.5 General Population
  66.   4.4 Healthcare, BY Formulation Type (USD Million)
  67.     4.4.1 Natural
  68.     4.4.2 Synthetic
  69.     4.4.3 Herbal
  70.     4.4.4 Flavored
  71.     4.4.5 Non-Flavored
  72. 5 SECTION V: COMPETITIVE ANALYSIS
  73.   5.1 Competitive Landscape
  74.     5.1.1 Overview
  75.     5.1.2 Competitive Analysis
  76.     5.1.3 Market share Analysis
  77.     5.1.4 Major Growth Strategy in the Healthcare
  78.     5.1.5 Competitive Benchmarking
  79.     5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  80.     5.1.7 Key developments and growth strategies
  81.       5.1.7.1 New Product Launch/Service Deployment
  82.       5.1.7.2 Merger & Acquisitions
  83.       5.1.7.3 Joint Ventures
  84.     5.1.8 Major Players Financial Matrix
  85.       5.1.8.1 Sales and Operating Income
  86.       5.1.8.2 Major Players R&D Expenditure. 2023
  87.   5.2 Company Profiles
  88.     5.2.1 Colgate-Palmolive (US)
  89.       5.2.1.1 Financial Overview
  90.       5.2.1.2 Products Offered
  91.       5.2.1.3 Key Developments
  92.       5.2.1.4 SWOT Analysis
  93.       5.2.1.5 Key Strategies
  94.     5.2.2 Procter & Gamble (US)
  95.       5.2.2.1 Financial Overview
  96.       5.2.2.2 Products Offered
  97.       5.2.2.3 Key Developments
  98.       5.2.2.4 SWOT Analysis
  99.       5.2.2.5 Key Strategies
  100.     5.2.3 Unilever (GB)
  101.       5.2.3.1 Financial Overview
  102.       5.2.3.2 Products Offered
  103.       5.2.3.3 Key Developments
  104.       5.2.3.4 SWOT Analysis
  105.       5.2.3.5 Key Strategies
  106.     5.2.4 Johnson & Johnson (US)
  107.       5.2.4.1 Financial Overview
  108.       5.2.4.2 Products Offered
  109.       5.2.4.3 Key Developments
  110.       5.2.4.4 SWOT Analysis
  111.       5.2.4.5 Key Strategies
  112.     5.2.5 GlaxoSmithKline (GB)
  113.       5.2.5.1 Financial Overview
  114.       5.2.5.2 Products Offered
  115.       5.2.5.3 Key Developments
  116.       5.2.5.4 SWOT Analysis
  117.       5.2.5.5 Key Strategies
  118.     5.2.6 Henkel (DE)
  119.       5.2.6.1 Financial Overview
  120.       5.2.6.2 Products Offered
  121.       5.2.6.3 Key Developments
  122.       5.2.6.4 SWOT Analysis
  123.       5.2.6.5 Key Strategies
  124.     5.2.7 Church & Dwight (US)
  125.       5.2.7.1 Financial Overview
  126.       5.2.7.2 Products Offered
  127.       5.2.7.3 Key Developments
  128.       5.2.7.4 SWOT Analysis
  129.       5.2.7.5 Key Strategies
  130.     5.2.8 Listerine (US)
  131.       5.2.8.1 Financial Overview
  132.       5.2.8.2 Products Offered
  133.       5.2.8.3 Key Developments
  134.       5.2.8.4 SWOT Analysis
  135.       5.2.8.5 Key Strategies
  136.     5.2.9 Oral-B (US)
  137.       5.2.9.1 Financial Overview
  138.       5.2.9.2 Products Offered
  139.       5.2.9.3 Key Developments
  140.       5.2.9.4 SWOT Analysis
  141.       5.2.9.5 Key Strategies
  142.   5.3 Appendix
  143.     5.3.1 References
  144.     5.3.2 Related Reports
  145. 6 LIST OF FIGURES
  146.   6.1 MARKET SYNOPSIS
  147.   6.2 SOUTH AMERICA MARKET ANALYSIS BY TREATMENT TYPE
  148.   6.3 SOUTH AMERICA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  149.   6.4 SOUTH AMERICA MARKET ANALYSIS BY END USER
  150.   6.5 SOUTH AMERICA MARKET ANALYSIS BY FORMULATION TYPE
  151.   6.6 KEY BUYING CRITERIA OF HEALTHCARE
  152.   6.7 RESEARCH PROCESS OF MRFR
  153.   6.8 DRO ANALYSIS OF HEALTHCARE
  154.   6.9 DRIVERS IMPACT ANALYSIS: HEALTHCARE
  155.   6.10 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
  156.   6.11 SUPPLY / VALUE CHAIN: HEALTHCARE
  157.   6.12 HEALTHCARE, BY TREATMENT TYPE, 2024 (% SHARE)
  158.   6.13 HEALTHCARE, BY TREATMENT TYPE, 2024 TO 2035 (USD Million)
  159.   6.14 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
  160.   6.15 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
  161.   6.16 HEALTHCARE, BY END USER, 2024 (% SHARE)
  162.   6.17 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Million)
  163.   6.18 HEALTHCARE, BY FORMULATION TYPE, 2024 (% SHARE)
  164.   6.19 HEALTHCARE, BY FORMULATION TYPE, 2024 TO 2035 (USD Million)
  165.   6.20 BENCHMARKING OF MAJOR COMPETITORS
  166. 7 LIST OF TABLES
  167.   7.1 LIST OF ASSUMPTIONS
  168.     7.1.1
  169.   7.2 South America MARKET SIZE ESTIMATES; FORECAST
  170.     7.2.1 BY TREATMENT TYPE, 2026-2035 (USD Million)
  171.     7.2.2 BY DISTRIBUTION CHANNEL, 2026-2035 (USD Million)
  172.     7.2.3 BY END USER, 2026-2035 (USD Million)
  173.     7.2.4 BY FORMULATION TYPE, 2026-2035 (USD Million)
  174.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  175.     7.3.1
  176.   7.4 ACQUISITION/PARTNERSHIP
  177.     7.4.1

South America Healthcare Market Segmentation

Healthcare By Treatment Type (USD Million, 2022-2035)

  • Mouthwash
  • Chewing Gum
  • Toothpaste
  • Sprays
  • Lozenges

Healthcare By Distribution Channel (USD Million, 2022-2035)

  • Pharmacies
  • Online Retail
  • Supermarkets
  • Health Stores
  • Direct Sales

Healthcare By End User (USD Million, 2022-2035)

  • Adults
  • Children
  • Elderly
  • Dental Patients
  • General Population

Healthcare By Formulation Type (USD Million, 2022-2035)

  • Natural
  • Synthetic
  • Herbal
  • Flavored
  • Non-Flavored

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions